White & Case has entered appearances for Gilead in Staley v. Gilead Sciences, while Arnold & Porter Kaye Scholer is representing Bristol-Myers Squibb; Drinker Biddle Reath represents Johnson & Johnson; and Holland & Knight reps Japan Tobacco.
Staley alleges that Gilead and the other drug companies have inflated the price of HIV medication through collusive licensing agreements, such as by combining Gilead compounds whose patents are expiring with other companies’ more recently patented compounds into fixed-dose combinations. The strategy is “crippling this nation’s ability to stop new HIV infections,” the plaintiffs contend in a May 14 complaint.
Gilead has said that it enters into partnerships with other companies to create life-saving therapies. “Any suggestion that we had improper motives is absolutely false,” the company has said.
Full Content: Law
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI